Rodriguez-Frias Edmundo A, Lee William M
Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Clin Liver Dis. 2007 Aug;11(3):641-62, viii. doi: 10.1016/j.cld.2007.06.007.
Although hepatotoxicity is a frequent concern with all medications, chemotherapeutic agents are more often implicated in causing liver damage than most other drug classes. In many instances, these reactions are considered dose related because cytotoxic therapy directed at rapidly growing cancer cells may readily impact hepatocytes even though they are dividing more slowly. Because the stakes (remission of cancer) are high, so are the risks that the oncologist and the patient are willing to assume. The dose of many chemotherapeutic agents is limited by the toxic effects on the lungs, bone marrow, kidneys, and gastrointestinal system, including the liver. An awareness of the toxic potential of each chemotherapeutic agent is necessary before initiation of new oncologic treatments.
尽管肝毒性是所有药物常见的问题，但与大多数其他药物类别相比，化疗药物更常引发肝损伤。在许多情况下，这些反应被认为与剂量相关，因为针对快速生长的癌细胞的细胞毒性疗法可能很容易影响肝细胞，即使它们的分裂速度较慢。由于风险（癌症缓解）很高，肿瘤学家和患者愿意承担的风险也很高。许多化疗药物的剂量受到对肺部、骨髓、肾脏和包括肝脏在内的胃肠道系统的毒性作用的限制。在开始新的肿瘤治疗之前，有必要了解每种化疗药物的潜在毒性。
